Latest News from ASCO in Action

Latest News from ASCO in Action

February 24, 2015

ASCO submitted comments to the Senate Health, Education, Labor, and Pensions (HELP) Committee on its white paper, Innovation for Healthier Americans, which aligns with the House of Representatives 21st Century Cures initiative to accelerate the pace of cures in the United States.

February 23, 2015

The American Society of Clinical Oncology (ASCO) recently submitted comments to the National Institutes of Health (NIH) on its proposed rule and draft policy on clinical trials registration and results submission in ClinicalTrials.gov.

February 23, 2015

On February 23, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to panobinostat (FARYDAK® capsules, Novartis Pharmaceuticals) in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent.  As a condition of this accelerated approval, FDA requires the sponsor to conduct a trial to verify and describe the clinical benefit of panobinostat for patients with multiple myeloma.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.